Castres, France

Ian Rilatt

This inventor holds 8 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignee: Pierre Fabre Medicament. Active years: 2019-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ian Rilatt. Retrieved from https://idiyas.com/inventor/ian-rilatt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Ian Rilatt - Innovative Inventor from Castres, FR

Introduction: Ian Rilatt is a talented inventor based in Castres, France, known for his groundbreaking contributions to various industries.

Latest Patents: Ian Rilatt holds several patents in the fields of technology and engineering, showcasing his continuous innovation and creativity.

Career Highlights: Throughout his career, Ian Rilatt has been recognized for his exceptional problem-solving skills and ability to turn ideas into practical solutions. His work has significantly impacted the way we approach challenges in different sectors.

Collaborations: Ian Rilatt has collaborated with leading companies and research institutions to bring his inventions to life. His partnerships have led to the development of cutting-edge technologies that have revolutionized the market.

Conclusion: Ian Rilatt's passion for innovation and dedication to his craft make him a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…